- Home
- SUZ vs ARWR Comparison
SUZ vs ARWR Comparison
Compare SUZ & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUZ | ARWR |
|---|---|---|
| Founded | 1924 | 2003 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 12.4B |
| IPO Year | 2002 | 2009 |
Fundamental Metrics
Financial Performance| Metric | SUZ | ARWR |
|---|---|---|
| Price | $9.06 | $86.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $83.40 |
| AVG Volume (30 Days) | ★ 3.4M | 1.3M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $13.28 | N/A |
| Revenue Next Year | $13.57 | N/A |
| P/E Ratio | $5.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.56 | $20.59 |
| 52 Week High | $11.54 | $95.49 |
Technical Indicators
Market Signals| Indicator | SUZ | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 69.62 | 52.63 |
| Support Level | $8.78 | $82.70 |
| Resistance Level | $9.68 | $87.83 |
| Average True Range (ATR) | 0.24 | 2.77 |
| MACD | 0.09 | -0.37 |
| Stochastic Oscillator | 92.55 | 41.17 |
Price Performance
Historical ComparisonAbout SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.